A hidden web of policy influence: The pharmaceutical industry's engagement with UK's All-Party Parliamentary Groups.
A hidden web of policy influence: The pharmaceutical industry's engagement with UK's All-Party Parliamentary Groups.
复制标题
DOI：
10.1371/journal.pone.0252551
复制
发表时间：
2021
期刊：
影响因子：
3.7
通讯作者：
Ozieranski P
中科院分区：
文献类型：
--
作者：
Rickard E;Ozieranski P
我们的目标是研究2012年至2018年间英国以健康为重点的各党派议会团体（appg）与制药行业之间的利益冲突。appg是一种非正式的跨党派团体，由英国下议院和上议院的成员围绕一个特定的话题运作。它们促进了议员与外部组织之间的接触，传播知识，并通过会议、出版物和活动引发辩论。我们确定了专注于身体或精神健康、福利、医疗保健或治疗的appg，并提取了在全党议会团体登记册上披露的外部捐助者的付款细节。我们确定了所有的捐赠者都是制药公司和制药行业资助的患者组织。我们确定146个与健康相关的appg中有16个（11%）存在利益冲突，这表明35家制药公司的付款价值1,211,345.81英镑（占所有与健康相关的appg收到的7,283,414.90英镑的16.6%）。两个appg（健康和癌症）获得了制药公司提供的总价值的一半以上。50家appg还收到了来自有利益冲突的患者组织的付款，报告显示，来自57个（84个）患者组织的304笔付款价值986,054.94英镑，这些患者组织在同一时期从制药公司收到了27,883,556.3英镑。总体而言，制药公司和制药工业资助的患者组织总共提供了2,197,400.75英镑（占与健康相关的APPG收到的所有资金的30.2%），并向58个（占146-39.7%）与健康相关的APPG支付了468笔（占1,177-39.7%），其中癌症APPG获得的资金最多。总之，我们发现了appg从制药公司获得可观收入的利益冲突的证据。需要全面审查制药业施加的政策影响，重点是可能参与其游说活动的行动者之间的关系。我们还提出了提高appg和制药公司支付报告透明度的方法。
Our objective was to examine conflicts of interest between the UK’s health-focused All-Party Parliamentary Groups (APPGs) and the pharmaceutical industry between 2012 and 2018. APPGs are informal cross-party groups revolving around a particular topic run by and for Members of the UK’s Houses of Commons and Lords. They facilitate engagement between parliamentarians and external organisations, disseminate knowledge, and generate debate through meetings, publications, and events. We identified APPGs focusing on physical or mental health, wellbeing, health care, or treatment and extracted details of their payments from external donors disclosed on the Register for All-Party Parliamentary Groups. We identified all donors which were pharmaceutical companies and pharmaceutical industry-funded patient organisations. We established that sixteen of 146 (11%) health-related APPGs had conflicts of interest indicated by reporting payments from thirty-five pharmaceutical companies worth £1,211,345.81 (16.6% of the £7,283,414.90 received by all health-related APPGs). Two APPGs (Health and Cancer) received more than half of the total value provided by drug companies. Fifty APPGs also had received payments from patient organisations with conflicts of interest, indicated by reporting 304 payments worth £986,054.94 from 57 (of 84) patient organisations which had received £27,883,556.3 from pharmaceutical companies across the same period. In total, drug companies and drug industry-funded patient organisations provided a combined total of £2,197,400.75 (30.2% of all funding received by health-related APPGs) and 468 (of 1,177–39.7%) payments to 58 (of 146–39.7%) health-related APPGs, with the APPG for Cancer receiving the most funding. In conclusion, we found evidence of conflicts of interests through APPGs receiving substantial income from pharmaceutical companies. Policy influence exerted by the pharmaceutical industry needs to be examined holistically, with an emphasis on relationships between actors potentially playing part in its lobbying campaigns. We also suggest ways of improving transparency of payment reporting by APPGs and pharmaceutical companies.
登录
查看更多内容
DOI：
10.15171/ijhpm.2018.20
发表时间：
2018-06-01
影响因子：
3.5
作者：
Fabbri A;Santos A;Mezinska S;Mulinari S;Mintzes B
通讯作者：
Mintzes B
DOI：
10.1177/0038038510369368
发表时间：
2010-08-01
影响因子：
2.9
作者：
Abraham, John
通讯作者：
Abraham, John
影响因子：
105.7
作者：
Goupil, Bruno;Balusson, Frederic;Frouard, Pierre
通讯作者：
Frouard, Pierre
影响因子：
--
作者：
Grande, David;Frosch, Dominick L.;Kahn, Barbara E.
通讯作者：
Kahn, Barbara E.
影响因子：
39
作者：
DeJong, Colette;Aguilar, Thomas;Dudley, R. Adams
通讯作者：
Dudley, R. Adams